Medroxyprogesterone
- Atc Codes:G03AC06#G03DA02#L02AB02
- CAS Codes:71-58-9#520-85-4
- PHARMGKB ID:71-58-9#520-85-4
Table of contents
- Brand Names
- Drug Combinations
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Genes that may be involved
- Substrate of
- Inhibits
- Induces
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Depocon, Farlutal, Prodafem, Sayana; Belgium: Provera, Veraplex; Bulgaria: Farlutal; Cyprus: Climanor, Progeron; Czech Republic: Medroplex, Provera, Sayana; Denmark: Provera; Estonia: Farlutal, Provera; Finland: Farlutal, Provera; France: Farlutal, Prodasone, Provera; Germany: Clinovir, Farlutal, Medroxin, MPA, Progevera, Provera, Sayana, Sedometril; Greece: Farlutal, Medroxyprogesterone, Neolut, Progevera, Provera; Hungary: Provera, Sayana; Ireland: Provera, Sayana; Italy: Farlutal, Provera; Latvia: Provera; Lithuania: Provera; Luxembourg: Farlutal, Mpa, Provera; Malta: Climanor; Netherlands: Medroxyprogesteronacetaat, Megestron, Provera, Sayana; Poland: Farlutal, Gestomikron, Provera, Sayana; Portugal: Provera; Romania: Farlutal, Provera; Slovakia: Medroplex, Provera; Slovenia: Provera; Spain: Farlutal, Progevera; Sweden: Provera; UK: Provera.
North America
Canada: Medroxy, Medroxyprogesterone, Novo-Medrone, Provera; USA: Medroxyprogesterone, Provera.
Latin America
Argentina: Farlutale, Livomedrox, Medrosterona, Medroxiprogesterona; Brazil: Acemedrox, Acetoflux, Contracep, Cycrin, Farlutal, Medroxitest, Medroxon, Provera; Mexico: Megestron, Provera.
Asia
Japan: Hysron, Medkiron, Nerfin, Provera.
Drug combinations
Medroxiprogesterone and Estradiol
Medroxyprogesterone and Estrogens (Conjugated)
Medroxyprogesterone, Bendroflumethiazide, and Meprobamate
Chemistry
Medroxyprogesterone Acetate: C~24~H~34~O~4~. Mw: 386.52. (1) Pregn-4-ene-3,20-dione, 17-(acetyloxy)-6-methyl-, (6α)-; (2) 17-Hydroxy-6α-methylpregn-4-ene-3,20-dione acetate. CAS-71-58-9; CAS-520-85-4 (medroxyprogesterone).
Pharmacologic Category
Hormones and Synthetic Substitutes; Progestins. Progestin Contraceptive. (ATC-Code: G03AC06; G03DA02 L02AB02).
Mechanism of action
Inhibits secretion of pituitary gonadotropins, which prevents follicular maturation and ovulation. Causes endometrial thinning.
Therapeutic use
Endometrial carcinoma or renal carcinoma. Secondary amenorrhea or abnormal uterine bleeding due to hormonal imbalance. Reduction of endometrial hyperplasia in nonhysterectomized postmenopausal women receiving conjugated estrogens. Prevention of pregnancy. Management of endometriosis-associated pain.
Pregnancy and lactiation implications
Potential adverse effects on fetus when administered within first 4 months of pregnancy (masculinization of the female fetus, hypospadias in male neonates, low birth weight).
Unlabeled use
Contraindications
Hypersensitivity to medroxyprogesterone or any component of the formulation. History of or current thrombophlebitis or venous thromboembolic disorders. Cerebral vascular disease. Severe hepatic dysfunction or disease. Carcinoma of breast or genital organs, undiagnosed vaginal bleeding. Missed abortion, diagnostic test for pregnancy, pregnancy.
Warnings and precautions
Prolonged use of medroxyprogesterone contraceptive injection may result in loss of bone mineral density, increased risk of invasive breast cancer in postmenopausal women using medroxyprogesterone acetate in combination with conjugated equine estrogens. Risk of dementia may be increased in postmenopausal women. Retinal vascular thrombosis: Discontinue pending examination in cases of sudden partial or complete vision loss, sudden onset of proptosis, diplopia, or migraine; discontinue permanently if papilledema or retinal vascular lesions observed on examination. Sudden or gradual, partial or complete loss of vision, proptosis or diplopia; papilledema, or retinal vascular lesions might occur. Use with caution in cardiovascular disease or dysfunction. Medroxyprogesterone in combination with estrogens should not be used to prevent coronary heart disease. Use with caution in history of depression. Use with caution in diabetes mellitus (may cause glucose intolerance). Use with caution in diseases which may be exacerbated by fluid retention, including asthma, epilepsy, migraine, diabetes, or renal dysfunction. Not for use prior to menarche.